Simlandi (Adalimumab-Ryvk) for Spondylitis

Overview
Simlandi is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with active ankylosing spondylitis (AS), along with various other chronic autoimmune conditions. Simlandi is a biosimilar of Humira (Adalimumab). As defined by the FDA, a biosimilar is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product. Simlandi is also known by its drug name, adalimumab-ryvk.

Simlandi belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. It is thought to work by inhibiting the action of a cytokine (chemical messenger) in the body called tumor necrosis factor, which is involved in inflammation and immune system activity. By blocking TNF, Simlandi can help reduce the inflammation and immune response that contribute to the symptoms of ankylosing spondylitis.

How do I take it?
According to the drug’s prescribing information, Simlandi is administered as a subcutaneous (under the skin) injection. For treating AS, it’s generally administered every other week. The medication should be taken exactly as prescribed by a health care provider.

Side effects
The FDA-approved label for Simlandi lists common side effects including infections (such as upper respiratory and sinusitis), injection site reactions, headache, and rash.

Rare but serious side effects listed for Simlandi include serious infections, including tuberculosis (TB), bacterial sepsis, and fungal infections; an increased risk of certain types of cancers including lymphoma; anaphylaxis (severe allergic reaction); reactivation of hepatitis B; diseases related to damage to protective sheath around nerves; low levels of certain blood cells; heart failure; and lupus-like syndrome.

For more information about this treatment, visit:

Label: Simlandi — Adalimumab-Ryvk Kit — DailyMed

Simlandi — Drugs.com